According to the top vaccine researcher at the US Walter Reed Army Institute of Research, scientists at the institute expect to know in the next few days if there's a concern that the COVID-19 vaccines might not work against a mutated variant of the virus that's rapidly spreading in parts of England, CNN reported on Monday.
Dr Nelson Michael, director of the Centre for Infectious Diseases Research at the Walter Reed Army Institute of Research, said that the Walter Reed scientists still expect the COVID-19 vaccine will be effective against this new virus variant.
Reportedly, on 17 December 2020, the Walter Reed team started examining genetic sequences of the new UK variant posted online by British researchers, with a computer analysis being done as a first step.
Michael said: "The computer analysis will allow us to gauge how much concern we should have", adding, "Other teams around the world are doing this analysis, too."
If the computer analysis shows there's a concern, then studies would need to be done in the laboratory and in animals to more definitively determine if the vaccine will work on this variant, CNN added.
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Lunit and CellCarta partner to advance AI-driven digital pathology in CDx development
Nektar Therapeutics presents rezpegaldesleukin data at 2026 AAD Annual Meeting
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting